The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Sickle-cell Anemia Therapeutics-Global Market Insights and Sales Trends 2024
Synopsis
Sickle cell disease (SCD) is a chronic, inherited blood disorder that impacts hemoglobin, a protein found in red blood cells (RBCs) that carries oxygen throughout the body. The disease is caused by a genetic mutation in the beta-chain of hemoglobin, which results in the formation of abnormal hemoglobin known as sickle hemoglobin (HbS).
The global Sickle-cell Anemia Therapeutics market size is expected to reach US$ 5067.2 million by 2029, growing at a CAGR of 15.0% from 2023 to 2029. The market is mainly driven by the significant applications of Sickle-cell Anemia Therapeutics in various end use industries. The expanding demands from the Child and Adult, are propelling Sickle-cell Anemia Therapeutics market. Blood Transfusion, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Pharmacotherapy segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by User. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Sickle-cell Anemia Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Sickle-cell Anemia Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Sickle-cell Anemia Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Sickle-cell Anemia Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Sickle-cell Anemia Therapeutics covered in this report include Addmedica, Gamida Cell, GlycoMimetics, Pfizer, Novartis, Global Blood Therapeutics, Micelle BioPharma, Bluebird Bio and Prolong Pharmaceuticals, etc.
The global Sickle-cell Anemia Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Addmedica
Gamida Cell
GlycoMimetics
Pfizer
Novartis
Global Blood Therapeutics
Micelle BioPharma
Bluebird Bio
Prolong Pharmaceuticals
Modus Therapeutics
Sangamo Biosciences
Bioverativ
Imara
Ironwood Pharmaceuticals
Global Sickle-cell Anemia Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Sickle-cell Anemia Therapeutics market, Segment by Type:
Blood Transfusion
Pharmacotherapy
Bone Marrow Transplant
Global Sickle-cell Anemia Therapeutics market, by User
Child
Adult
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by User, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Sickle-cell Anemia Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Sickle cell disease (SCD) is a chronic, inherited blood disorder that impacts hemoglobin, a protein found in red blood cells (RBCs) that carries oxygen throughout the body. The disease is caused by a genetic mutation in the beta-chain of hemoglobin, which results in the formation of abnormal hemoglobin known as sickle hemoglobin (HbS).
The global Sickle-cell Anemia Therapeutics market size is expected to reach US$ 5067.2 million by 2029, growing at a CAGR of 15.0% from 2023 to 2029. The market is mainly driven by the significant applications of Sickle-cell Anemia Therapeutics in various end use industries. The expanding demands from the Child and Adult, are propelling Sickle-cell Anemia Therapeutics market. Blood Transfusion, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Pharmacotherapy segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by User. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Sickle-cell Anemia Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Sickle-cell Anemia Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Sickle-cell Anemia Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Sickle-cell Anemia Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Sickle-cell Anemia Therapeutics covered in this report include Addmedica, Gamida Cell, GlycoMimetics, Pfizer, Novartis, Global Blood Therapeutics, Micelle BioPharma, Bluebird Bio and Prolong Pharmaceuticals, etc.
The global Sickle-cell Anemia Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Addmedica
Gamida Cell
GlycoMimetics
Pfizer
Novartis
Global Blood Therapeutics
Micelle BioPharma
Bluebird Bio
Prolong Pharmaceuticals
Modus Therapeutics
Sangamo Biosciences
Bioverativ
Imara
Ironwood Pharmaceuticals
Global Sickle-cell Anemia Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Sickle-cell Anemia Therapeutics market, Segment by Type:
Blood Transfusion
Pharmacotherapy
Bone Marrow Transplant
Global Sickle-cell Anemia Therapeutics market, by User
Child
Adult
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by User, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Sickle-cell Anemia Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Sickle-cell Anemia Therapeutics
1.1 Sickle-cell Anemia Therapeutics Market Overview
1.1.1 Sickle-cell Anemia Therapeutics Product Scope
1.1.2 Sickle-cell Anemia Therapeutics Market Status and Outlook
1.2 Global Sickle-cell Anemia Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Sickle-cell Anemia Therapeutics Market Size by Region (2018-2029)
1.4 Global Sickle-cell Anemia Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Sickle-cell Anemia Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Sickle-cell Anemia Therapeutics Market Size (2018-2029)
1.6.1 North America Sickle-cell Anemia Therapeutics Market Size (2018-2029)
1.6.2 Europe Sickle-cell Anemia Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Sickle-cell Anemia Therapeutics Market Size (2018-2029)
1.6.4 Latin America Sickle-cell Anemia Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Sickle-cell Anemia Therapeutics Market Size (2018-2029)
2 Sickle-cell Anemia Therapeutics Market by Type
2.1 Introduction
2.1.1 Blood Transfusion
2.1.2 Pharmacotherapy
2.1.3 Bone Marrow Transplant
2.2 Global Sickle-cell Anemia Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Sickle-cell Anemia Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Sickle-cell Anemia Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Sickle-cell Anemia Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Sickle-cell Anemia Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Sickle-cell Anemia Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Sickle-cell Anemia Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Sickle-cell Anemia Therapeutics Revenue Breakdown by Type (2018-2029)
3 Sickle-cell Anemia Therapeutics Market Overview by User
3.1 Introduction
3.1.1 Child
3.1.2 Adult
3.2 Global Sickle-cell Anemia Therapeutics Market Size by User: 2018 VS 2022 VS 2029
3.2.1 Global Sickle-cell Anemia Therapeutics Historic Market Size by User (2018-2023)
3.2.2 Global Sickle-cell Anemia Therapeutics Forecasted Market Size by User (2024-2029)
3.3 Key Regions Market Size by User
3.3.1 North America Sickle-cell Anemia Therapeutics Revenue Breakdown by User (2018-2029)
3.3.2 Europe Sickle-cell Anemia Therapeutics Revenue Breakdown by User (2018-2029)
3.3.3 Asia-Pacific Sickle-cell Anemia Therapeutics Revenue Breakdown by User (2018-2029)
3.3.4 Latin America Sickle-cell Anemia Therapeutics Revenue Breakdown by User (2018-2029)
3.3.5 Middle East and Africa Sickle-cell Anemia Therapeutics Revenue Breakdown by User (2018-2029)
4 Sickle-cell Anemia Therapeutics Competition Analysis by Players
4.1 Global Sickle-cell Anemia Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Sickle-cell Anemia Therapeutics as of 2022)
4.3 Date of Key Players Enter into Sickle-cell Anemia Therapeutics Market
4.4 Global Top Players Sickle-cell Anemia Therapeutics Headquarters and Area Served
4.5 Key Players Sickle-cell Anemia Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Sickle-cell Anemia Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Addmedica
5.1.1 Addmedica Profile
5.1.2 Addmedica Main Business
5.1.3 Addmedica Sickle-cell Anemia Therapeutics Products, Services and Solutions
5.1.4 Addmedica Sickle-cell Anemia Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Addmedica Recent Developments
5.2 Gamida Cell
5.2.1 Gamida Cell Profile
5.2.2 Gamida Cell Main Business
5.2.3 Gamida Cell Sickle-cell Anemia Therapeutics Products, Services and Solutions
5.2.4 Gamida Cell Sickle-cell Anemia Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Gamida Cell Recent Developments
5.3 GlycoMimetics
5.3.1 GlycoMimetics Profile
5.3.2 GlycoMimetics Main Business
5.3.3 GlycoMimetics Sickle-cell Anemia Therapeutics Products, Services and Solutions
5.3.4 GlycoMimetics Sickle-cell Anemia Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Pfizer Recent Developments
5.4 Pfizer
5.4.1 Pfizer Profile
5.4.2 Pfizer Main Business
5.4.3 Pfizer Sickle-cell Anemia Therapeutics Products, Services and Solutions
5.4.4 Pfizer Sickle-cell Anemia Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Pfizer Recent Developments
5.5 Novartis
5.5.1 Novartis Profile
5.5.2 Novartis Main Business
5.5.3 Novartis Sickle-cell Anemia Therapeutics Products, Services and Solutions
5.5.4 Novartis Sickle-cell Anemia Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Novartis Recent Developments
5.6 Global Blood Therapeutics
5.6.1 Global Blood Therapeutics Profile
5.6.2 Global Blood Therapeutics Main Business
5.6.3 Global Blood Therapeutics Sickle-cell Anemia Therapeutics Products, Services and Solutions
5.6.4 Global Blood Therapeutics Sickle-cell Anemia Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 Global Blood Therapeutics Recent Developments
5.7 Micelle BioPharma
5.7.1 Micelle BioPharma Profile
5.7.2 Micelle BioPharma Main Business
5.7.3 Micelle BioPharma Sickle-cell Anemia Therapeutics Products, Services and Solutions
5.7.4 Micelle BioPharma Sickle-cell Anemia Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Micelle BioPharma Recent Developments
5.8 Bluebird Bio
5.8.1 Bluebird Bio Profile
5.8.2 Bluebird Bio Main Business
5.8.3 Bluebird Bio Sickle-cell Anemia Therapeutics Products, Services and Solutions
5.8.4 Bluebird Bio Sickle-cell Anemia Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 Bluebird Bio Recent Developments
5.9 Prolong Pharmaceuticals
5.9.1 Prolong Pharmaceuticals Profile
5.9.2 Prolong Pharmaceuticals Main Business
5.9.3 Prolong Pharmaceuticals Sickle-cell Anemia Therapeutics Products, Services and Solutions
5.9.4 Prolong Pharmaceuticals Sickle-cell Anemia Therapeutics Revenue (US$ Million) & (2018-2023)
5.9.5 Prolong Pharmaceuticals Recent Developments
5.10 Modus Therapeutics
5.10.1 Modus Therapeutics Profile
5.10.2 Modus Therapeutics Main Business
5.10.3 Modus Therapeutics Sickle-cell Anemia Therapeutics Products, Services and Solutions
5.10.4 Modus Therapeutics Sickle-cell Anemia Therapeutics Revenue (US$ Million) & (2018-2023)
5.10.5 Modus Therapeutics Recent Developments
5.11 Sangamo Biosciences
5.11.1 Sangamo Biosciences Profile
5.11.2 Sangamo Biosciences Main Business
5.11.3 Sangamo Biosciences Sickle-cell Anemia Therapeutics Products, Services and Solutions
5.11.4 Sangamo Biosciences Sickle-cell Anemia Therapeutics Revenue (US$ Million) & (2018-2023)
5.11.5 Sangamo Biosciences Recent Developments
5.12 Bioverativ
5.12.1 Bioverativ Profile
5.12.2 Bioverativ Main Business
5.12.3 Bioverativ Sickle-cell Anemia Therapeutics Products, Services and Solutions
5.12.4 Bioverativ Sickle-cell Anemia Therapeutics Revenue (US$ Million) & (2018-2023)
5.12.5 Bioverativ Recent Developments
5.13 Imara
5.13.1 Imara Profile
5.13.2 Imara Main Business
5.13.3 Imara Sickle-cell Anemia Therapeutics Products, Services and Solutions
5.13.4 Imara Sickle-cell Anemia Therapeutics Revenue (US$ Million) & (2018-2023)
5.13.5 Imara Recent Developments
5.14 Ironwood Pharmaceuticals
5.14.1 Ironwood Pharmaceuticals Profile
5.14.2 Ironwood Pharmaceuticals Main Business
5.14.3 Ironwood Pharmaceuticals Sickle-cell Anemia Therapeutics Products, Services and Solutions
5.14.4 Ironwood Pharmaceuticals Sickle-cell Anemia Therapeutics Revenue (US$ Million) & (2018-2023)
5.14.5 Ironwood Pharmaceuticals Recent Developments
6 North America
6.1 North America Sickle-cell Anemia Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Sickle-cell Anemia Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Sickle-cell Anemia Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Sickle-cell Anemia Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Sickle-cell Anemia Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Sickle-cell Anemia Therapeutics Market Dynamics
11.1 Sickle-cell Anemia Therapeutics Industry Trends
11.2 Sickle-cell Anemia Therapeutics Market Drivers
11.3 Sickle-cell Anemia Therapeutics Market Challenges
11.4 Sickle-cell Anemia Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
